References

Frequency, grades of toxicity, and predictors of hepatotoxicity and Acute Kidney Injury with Remdesivir in COVID-19 patients: a multicenter retrospective cohort Study

10.3390/healthcare13172143 · 2025 · External reference

Remdesivir; molecular and functional measures of mitochondrial safety

10.1016/j.taap.2021.115783 · 2021 · External reference

Increased 1-year mortality in haemodialysis patients with COVID-19: a prospective, observational study

10.1093/ckj/sfab248 · 2022 · External reference

Kimmel PL. Acute kidney injury and chronic kidney disease as interconnected syndromes

10.1056/nejmra1214243 · 2014 · External reference

Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study

10.1016/s2214-109x(20)30264-3 · 2020 · External reference

Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA

10.1093/ndt/gfaa314 · 2021 · External reference

Remdesivir increases mtDNA copy number causing mild alterations to oxidative phosphorylation

10.1038/s41598-023-42704-y · 2023 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Molecular pathways driving omeprazole nephrotoxicity

10.1016/j.redox.2020.101464 · 2020 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

Remdesivir and acute renal failure: a potential safety signal from disproportionality analysis of the WHO safety database

10.1002/cpt.2145 · 2021 · External reference

Remdesivir for 5 or 10 days in patients with Severe Covid-19

10.1056/nejmoa2015301 · 2020 · External reference

Efficient incorporation and template-dependent polymerase inhibition are major determinants for the broad-spectrum antiviral activity of remdesivir

10.1016/j.jbc.2021.101529 · 2022 · External reference

The RIPK3-IL-6 axis mediates kidney injury in cytokine storm syndrome

10.1038/s41419-026-08686-1 · 2026 · External reference

Characterization of a renal tubular epithelial cell line which secretes the autologous target antigen of autoimmune experimental interstitial nephritis

10.1083/jcb.107.4.1359 · 1988 · External reference

Mitotherapy inhibits against tenofovir induced nephrotoxicity on rat renal proximal tubular cells

10.1016/j.bbrep.2024.101669 · 2024 · External reference

Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study

10.1007/s00134-015-3934-7 · 2015 · External reference

Safety, tolerability, and pharmacokinetics of Remdesivir, an antiviral for treatment of COVID-19, in healthy subjects

10.1111/cts.12840 · 2020 · External reference

Cytokine cooperation in renal tubular cell injury: the role of TWEAK

10.1038/sj.ki.5001866 · 2006 · External reference

KDIGO 2012 Clinical Practice Guideline for the evaluation and management of chronic kidney disease

2013 · External reference

Mechanism of SARS-CoV-2 polymerase stalling by remdesivir

10.1038/s41467-020-20542-0 · 2021 · External reference

COVID-19 patients with kidney disease and completion of Remdesivir treatment

10.14423/smj.0000000000001901 · 2025 · External reference

Drug-Induced hospital-acquired acute kidney injury in China: a Multicenter Cross-Sectional Survey

10.1159/000510455 · 2021 · External reference

Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD)

10.1002/jps.22109 · 2010 · External reference

Acute kidney injury is aggravated in aged mice by the exacerbation of proinflammatory processes

10.3389/fphar.2021.662020 · 2021 · External reference

Deferasirox-induced iron depletion promotes BclxL downregulation and death of proximal tubular cells

10.1038/srep41510 · 2017 · External reference

TWEAK and RIPK1 mediate a second wave of cell death during AKI

10.1073/pnas.1716578115 · 2018 · External reference

The potential of remdesivir to affect function, metabolism and proliferation of cardiac and kidney cells in vitro

10.1007/s00204-022-03306-1 · 2022 · External reference

A simple practice guide for dose conversion between animals and human

10.4103/0976-0105.177703 · 2016 · External reference

CKD as a risk factor for severe COVID-19: a critical look back and lessons for the future

10.1093/ndt/gfad216 · 2024 · External reference

Drug-Induced acute kidney injury

10.2215/cjn.11290821 · 2022 · External reference

Impact of recurrent acute kidney injury on patient outcomes

10.1159/000486744 · 2018 · External reference

Renal and hepatic toxicity analysis of Remdesivir formulations: does what is on the inside really count?

10.1128/aac.01045-21 · 2021 · External reference

Potential kidney damage associated with the use of remdesivir for COVID-19: analysis of a pharmacovigilance database

10.1590/0102-311x00077721 · 2021 · External reference

Efficacy and safety of remdesivir in people with impaired kidney function hospitalized for COVID-19 pneumonia: a randomized clinical trial

10.1093/cid/ciae333 · 2024 · External reference

Pharmacokinetics of remdesivir in a COVID-19 patient with end-stage renal disease on intermittent haemodialysis

10.1093/jac/dkaa500doi.org/10.1093/jac/dkaa500 · 2021 · External reference

Safety evaluation of remdesivir administration in patients with severe renal impairment and coronavirus disease: a systematic review and meta-analysis

10.1186/s12879-025-11153-5 · 2025 · External reference

Aristolochic acid I induces proximal tubule injury through ROS/HMGB1/mt DNA mediated activation of TLRs

10.1111/jcmm.17451 · 2022 · External reference

Fighting the unbearable lightness of neglecting kidney health: the decade of the kidney

10.1093/ckj/sfab070 · 2021 · External reference

Acute kidney injury associated with remdesivir: a comprehensive pharmacovigilance analysis of COVID-19 reports in FAERS

10.3389/fphar.2022.692828 · 2022 · External reference

Off-target in vitro profiling demonstrates that remdesivir is a highly selective antiviral agent

10.1128/aac.02237-20 · 2021 · External reference

Nephropathy induced by cisplatin results from mitochondrial disruption, impaired energy metabolism, altered expression of renal transporters, and accumulation of urinary toxins

10.1016/j.jtemb.2024.127553 · 2024 · External reference

Clinical pharmacokinetics and safety of remdesivir in phase I participants with varying degrees of renal impairment

10.1007/s40262-024-01453-5 · 2025 · External reference